Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 19, 2026, 10:28 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 181 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Diluent Clear all
Completed Phase 1 Interventional Accepts healthy volunteers Results available

CC100: Safety and Tolerability of Single Doses

NCT02050334
View directory record Official record
Conditions
Healthy
Interventions
CC100, Placebo
Drug
Lead sponsor
Chemigen, LLC
Industry
Eligibility
18 Years to 64 Years
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2015
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Apr 30, 2015 · Synced Oct 19, 2026, 10:28 PM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

pH1N1 Blinded Challenge Study

NCT07110532
View directory record Official record
Conditions
Influenza
Interventions
A/Arkansas/08/2020 (pH1N1), Sham/Diluent (1X SPG+Arg+Gel)
Biological · Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 55 Years
Enrollment
90 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
2
States / cities
Baltimore, Maryland • Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Oct 16, 2026 · Synced Oct 19, 2026, 10:28 PM EDT
Recruiting Phase 4 Interventional Accepts healthy volunteers

Durability of Vaccine Responses

NCT05801978
View directory record Official record
Conditions
Vaccine Response
Interventions
Live Attenuated Yellow Fever 17D Vaccine, Quadrivalent seasonal influenza vaccine
Biological
Lead sponsor
Emory University
Other
Eligibility
18 Years to 50 Years
Enrollment
66 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2027
U.S. locations
3
States / cities
Atlanta, Georgia • Decatur, Georgia
Source: ClinicalTrials.gov public record
Updated Jul 17, 2026 · Synced Oct 19, 2026, 10:28 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Study Combining Bortezomib With High Dose Melphalan to Treat Multiple Myeloma

NCT00784823
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Bortezomib 1 mg/m2, Bortezomib 1.3 mg/m2, Bortezomib 1.6 mg/m2, Melphalan
Drug
Lead sponsor
Hackensack Meridian Health
Other
Eligibility
18 Years to 76 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2013
U.S. locations
1
States / cities
Hackensack, New Jersey
Source: ClinicalTrials.gov public record
Updated Aug 11, 2022 · Synced Oct 19, 2026, 10:28 PM EDT
Completed Phase 2 Interventional Results available

Study to Assess Safety and Clinical Activity of Local MBN-101 in Treatment of Infected Bone Sites

NCT02436876
View directory record Official record
Conditions
Bacterial Infection
Interventions
MBN-101, Placebo
Drug · Other
Lead sponsor
Microbion Corporation
Industry
Eligibility
18 Years to 75 Years
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
6
States / cities
San Francisco, California • Baltimore, Maryland • Columbus, Ohio + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 30, 2021 · Synced Oct 19, 2026, 10:28 PM EDT
Completed Phase 3 Interventional Results available

Safety and Effectiveness of AZLI (an Inhaled Antibiotic) in Adults With Non-Cystic Fibrosis Bronchiectasis

NCT01314716
View directory record Official record
Conditions
Bronchiectasis
Interventions
AZLI, Placebo
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
274 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
33
States / cities
Florence, Alabama • Flagstaff, Arizona • Peoria, Arizona + 30 more
Source: ClinicalTrials.gov public record
Updated Apr 16, 2014 · Synced Oct 19, 2026, 10:28 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

Gene Therapy Using Anti-Her-2 Cells to Treat Metastatic Cancer

NCT00924287
View directory record Official record
Conditions
Metastatic Cancer
Interventions
in vitro tumor reactive, chimeric T cell receptor (CAR ) gene-transduced PBL plus IV aldesleukin, Cyclophosphamide, Fludarabine, Mesna
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 28, 2015 · Synced Oct 19, 2026, 10:28 PM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

Nitric Oxide, LPS and the Pathogenesis of Asthma Phase II

NCT00643058
View directory record Official record
Conditions
Healthy
Interventions
LPS endotoxin
Biological
Lead sponsor
John Sundy
Other
Eligibility
18 Years to 40 Years
Enrollment
70 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003 – 2009
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 16, 2013 · Synced Oct 19, 2026, 10:28 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Dose-Dependent Effect of Intranasal Insulin in Humans Using Functional Magnetic Resonance Imaging (fMRI)

NCT06144255
View directory record Official record
Conditions
Healthy
Interventions
Intranasal insulin
Drug
Lead sponsor
Florian Schmitzberger
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Mar 21, 2024 · Synced Oct 19, 2026, 10:28 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Safety/Efficacy Study of Seqirus A/H7N9 IIV With or Without MF59(R) Adjuvant to Prevent Avian Influenza

NCT03682120
View directory record Official record
Conditions
Avian Influenza, Influenza Immunisation
Interventions
A/H7N9, MF59, Phosphate Buffered Saline (PBS) diluent
Biological · Drug · Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 64 Years
Enrollment
372 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2020
U.S. locations
7
States / cities
Birmingham, Alabama • St Louis, Missouri • Cincinnati, Ohio + 4 more
Source: ClinicalTrials.gov public record
Updated May 17, 2021 · Synced Oct 19, 2026, 10:28 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

A Clinical Trial of CSL's 2009 H1N1 Influenza Vaccine (CSL425) in Healthy Adults in the USA

NCT00958126
View directory record Official record
Conditions
Influenza
Interventions
CSL425, Placebo
Biological
Lead sponsor
Seqirus
Industry
Eligibility
18 Years and older
Enrollment
1,313 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
11
States / cities
Huntsville, Alabama • San Diego, California • Melbourne, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Nov 21, 2017 · Synced Oct 19, 2026, 10:28 PM EDT
Terminated Phase 1 Interventional

Study Evaluating MST-997 in Advanced Malignant Solid Tumors

NCT00277836
View directory record Official record
Conditions
Neoplasms
Interventions
MST-997
Drug
Lead sponsor
Wyeth is now a wholly owned subsidiary of Pfizer
Industry
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Dec 8, 2006 · Synced Oct 19, 2026, 10:28 PM EDT
Completed Phase 2 Interventional Results available

17AAG to Treat Kidney Tumors in Von Hippel-Lindau Disease

NCT00088374
View directory record Official record
Conditions
Hippel-Lindau Disease, Kidney Cancer
Interventions
17 allylamino-17-demethoxygeldanamycin, 18 FDG (Fludeoxyglucose 18F), [15-O] H2O, EPL diluent
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2009
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 27, 2012 · Synced Oct 19, 2026, 10:28 PM EDT
Terminated Phase 4 Interventional Results available

Does Low-does Cervical Epidural Lidocaine Cause Transient Weakness?

NCT03382925
View directory record Official record
Conditions
Cervical Radiculopathy
Interventions
cervical interlaminar with lidocaine, cervical interlaminar with normal saline, Lidocaine, Triamcinolone Acetonide, Normal saline
Procedure · Drug
Lead sponsor
University of Utah
Other
Eligibility
18 Years to 80 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Nov 25, 2022 · Synced Oct 19, 2026, 10:28 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety and Immunogenicity of IVX-A12 in Healthy Older Adults

NCT05664334
View directory record Official record
Conditions
Healthy
Interventions
IVX-121, IVX-241, Placebo, MF59®
Biological · Other
Lead sponsor
Icosavax, Inc.
Industry
Eligibility
60 Years to 75 Years
Enrollment
140 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2024
U.S. locations
4
States / cities
Hollywood, Florida • Atlanta, Georgia • Omaha, Nebraska + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 5, 2024 · Synced Oct 19, 2026, 10:28 PM EDT
Completed Phase 3 Interventional Results available

Epothilone (Ixabepilone) Plus Capecitabine Versus Capecitabine Alone in Patients With Advanced Breast Cancer

NCT00082433
View directory record Official record
Conditions
Cancer, Breast Cancer
Interventions
Ixabepilone + Capecitabine, Capecitabine
Drug
Lead sponsor
R-Pharm
Industry
Eligibility
18 Years and older · Female only
Enrollment
1,221 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2008
U.S. locations
34
States / cities
Tucson, Arizona • Beverly Hills, California • Corona, California + 31 more
Source: ClinicalTrials.gov public record
Updated Nov 2, 2020 · Synced Oct 19, 2026, 10:28 PM EDT
Completed Phase 2 Interventional Results available

A Phase II, Multicenter, Randomized, Placebo -Controlled, Study To Evaluate The Efficacy and Safety Of Intramuscular Peramivir 600 mg In Subjects With Uncomplicated Acute Influenza

NCT00705406
View directory record Official record
Conditions
Acute, Uncomplicated Human Influenza
Interventions
Peramivir, Placebo
Drug
Lead sponsor
BioCryst Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
405 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
67
States / cities
Birmingham, Alabama • Phoenix, Arizona • Jonesboro, Arkansas + 58 more
Source: ClinicalTrials.gov public record
Updated Feb 16, 2015 · Synced Oct 19, 2026, 10:28 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Intranasal Insulin for Improving Cognitive Function in Multiple Sclerosis

NCT02988401
View directory record Official record
Conditions
Multiple Sclerosis, Relapsing-Remitting, Multiple Sclerosis, Secondary Progressive, Multiple Sclerosis, Primary Progressive
Interventions
Insulin, Placebo (Sterile diluent)
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 70 Years
Enrollment
105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 10, 2023 · Synced Oct 19, 2026, 10:28 PM EDT
Completed Phase 2 Interventional Results available

Treatment With Omalizumab to Improve the Asthmatic Response to Rhinovirus Experimental Infection With Rhinovirus

NCT02388997
View directory record Official record
Conditions
Asthma
Interventions
omalizumab, Rhinovirus (strain 16)
Drug · Biological
Lead sponsor
University of Virginia
Other
Eligibility
18 Years to 40 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Jul 9, 2018 · Synced Oct 19, 2026, 10:28 PM EDT
Completed Phase 2 Interventional

DMT310-001 Topical in the Treatment of Acne Vulgaris

NCT03536637
View directory record Official record
Conditions
Acne Vulgaris
Interventions
DMT310, Hydrogen Peroxide, Placebo
Drug
Lead sponsor
Dermata Therapeutics
Industry
Eligibility
12 Years and older
Enrollment
121 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
9
States / cities
San Diego, California • Saint Joseph, Missouri • Henderson, Nevada + 6 more
Source: ClinicalTrials.gov public record
Updated Jul 22, 2020 · Synced Oct 19, 2026, 10:28 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Targeted Intramyocardial Delivery of Auto CD34+ Stem Cells for Improving Exercise Capacity in Subjects With Refractory Angina

NCT01508910
View directory record Official record
Conditions
Chronic Myocardial Ischemia, Refractory Angina Pectoris, Advanced Coronary Heart Disease
Interventions
Auto-CD34+ cells, Placebo: Diluent used to suspend Auto-CD34+ cells, Standard of care
Biological · Other
Lead sponsor
Lisata Therapeutics, Inc.
Industry
Eligibility
21 Years to 80 Years
Enrollment
291 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
41
States / cities
Birmingham, Alabama • Gilbert, Arizona • Phoenix, Arizona + 38 more
Source: ClinicalTrials.gov public record
Updated Dec 19, 2018 · Synced Oct 19, 2026, 10:28 PM EDT
Withdrawn Phase 2 Interventional

Study to Evaluate the Efficacy of IN STI-9199 in Treating Symptomatic COVID-19 in Outpatient Adults and Adolescents

NCT05372783
View directory record Official record
Conditions
COVID-19
Interventions
STI-9199, Placebo
Drug
Lead sponsor
Sorrento Therapeutics, Inc.
Industry
Eligibility
12 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Chula Vista, California
Source: ClinicalTrials.gov public record
Updated Feb 13, 2023 · Synced Oct 19, 2026, 10:28 PM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers Results available

Evaluating the Infectivity, Safety and Immunogenicity of a Recombinant Live-Attenuated Respiratory Syncytial Virus Vaccine (RSV LID cp ΔM2-2) in RSV-Seronegative Infants 6 to 24 Months of Age

NCT02890381
View directory record Official record
Conditions
Respiratory Syncytial Virus Infections
Interventions
RSV LID cp ΔM2-2 Vaccine, Placebo
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
6 Months to 24 Months
Enrollment
17 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
5
States / cities
Los Angeles, California • Aurora, Colorado • Chicago, Illinois + 2 more
Source: ClinicalTrials.gov public record
Updated Nov 5, 2021 · Synced Oct 19, 2026, 10:28 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

COVID Card Pilot Study to Detect Antibodies to SARS-CoV-2

NCT05196932
View directory record Official record
Conditions
COVID-19, SARS-CoV2 Infection
Interventions
Novel point-of-care, semi-quantitative test for SARS-CoV-2 antibodies
Device
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years and older
Enrollment
56 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated May 10, 2023 · Synced Oct 19, 2026, 10:28 PM EDT